STUB1 and Miyoshi myopathy: In this study (see Supplementary Fig. 1), we investigate the prevalence of CHIP at the time of ASCT in MM patients and find that it confers worse clinical outcomes in relation to a faster MM progression rate but does not pose an increased risk of TMN.